(Reuters) - Amgen Inc
Share gains for the company have been due in part to pledges by Chief Executive Officer Robert Bradway, since he took the helm of the California biotech in May 2012, to return 60 percent of adjusted net income to shareholders through dividends and stock buybacks, Barron's said.
"The shares could rise another 20 percent to $120, largely from staying the course," Barron's said, noting that Amgen has approved $12 billion in stock buybacks, initiated a dividend and raised it twice in the past two years.
(Reporting by Ransdell Pierson; Editing by Theodore d'Afflisio)
(c) Copyright Thomson Reuters 2013. Check for restrictions at: http://about.reuters.com/fulllegal.asp